The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) reached all time low today, Nov, 3 and still has $3.73 target or 11.00% below today’s $4.19 share price. This indicates more downside for the $144.42 million company. This technical setup was reported by Barchart.com. If the $3.73 PT is reached, the company will be worth $15.89M less.
Trading stocks at an all time low is not easy. Stock at an all time low usually experience even more downside due to very negative fundament. Even thought the pullback rate is high, shorting is not an easy job because the risk of being wrong is big and the risk-reward ratio is always worse than if trading lon only. The stock decreased 32.96% or $2.06 during the last trading session, hitting $4.19. About 6.05 million shares traded hands or 220.11% up from the average. PTC Therapeutics, Inc. (NASDAQ:PTCT) has declined 7.54% since April 1, 2016 and is downtrending. It has underperformed by 8.76% the S&P500.
Analysts await PTC Therapeutics, Inc. (NASDAQ:PTCT) to report earnings on November, 14. They expect $-1.19 EPS, up 6.30% or $0.08 from last year’s $-1.27 per share. After $-1.14 actual EPS reported by PTC Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 4.39% negative EPS growth.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Ratings Coverage
Out of 7 analysts covering PTC Therapeutics (NASDAQ:PTCT), 2 rate it a “Buy”, 0 “Sell”, while 5 “Hold”. This means 29% are positive. PTC Therapeutics has been the topic of 16 analyst reports since July 31, 2015 according to StockzIntelligence Inc. The firm earned “Neutral” rating on Tuesday, July 26 by Credit Suisse. The firm earned “Neutral” rating on Tuesday, February 23 by JP Morgan. As per Thursday, February 25, the company rating was maintained by Oppenheimer. The firm earned “Hold” rating on Friday, October 23 by Jefferies. The firm has “Outperform” rating by RBC Capital Markets given on Friday, July 31. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Outperform” rating by Wedbush on Wednesday, February 24. The company was downgraded on Wednesday, November 25 by Jefferies. The firm has “Buy” rating by Citigroup given on Tuesday, August 25. The stock of PTC Therapeutics, Inc. (NASDAQ:PTCT) earned “Neutral” rating by Citigroup on Wednesday, February 24. The company was initiated on Wednesday, January 20 by Credit Suisse.
According to Zacks Investment Research, “PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.”
Insitutional Activity: The institutional sentiment increased to 1.23 in 2016 Q2. Its up 0.40, from 0.83 in 2016Q1. The ratio is positive, as 17 funds sold all PTC Therapeutics, Inc. shares owned while 30 reduced positions. 17 funds bought stakes while 41 increased positions. They now own 28.13 million shares or 3.23% less from 29.06 million shares in 2016Q1.
Alliancebernstein Limited Partnership last reported 75,650 shares in the company. Dimensional Fund Advisors Limited Partnership holds 100,783 shares or 0% of its portfolio. Voya Investment Mngmt Ltd, a Georgia-based fund reported 14,593 shares. Moreover, Sei has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 29,081 shares. Metropolitan Life Insurance Ny accumulated 0% or 23,703 shares. Eagle Glob Advsr Limited Company last reported 0.01% of its portfolio in the stock. D E Shaw Inc has 0% invested in the company for 28,761 shares. Davenport has invested 0% of its portfolio in PTC Therapeutics, Inc. (NASDAQ:PTCT). The New York-based Springbok Cap Mgmt Limited Liability Company has invested 0.01% in PTC Therapeutics, Inc. (NASDAQ:PTCT). Moreover, Svcs Automobile Association has 0% invested in PTC Therapeutics, Inc. (NASDAQ:PTCT) for 26,760 shares. Camber Capital Mgmt Ltd Limited Liability Company, a Massachusetts-based fund reported 1.50 million shares. Manufacturers Life The last reported 0% of its portfolio in the stock. Millennium Limited Liability accumulated 0% or 52,002 shares. Blackrock Fund Advsr, a California-based fund reported 1.30M shares. Pub Employees Retirement Association Of Colorado accumulated 8,019 shares or 0% of the stock.
More notable recent PTC Therapeutics, Inc. (NASDAQ:PTCT) news were published by: Fool.com which released: “Why PTC Therapeutics, Inc. Is Crashing Today” on October 17, 2016, also Reuters.com with their article: “BRIEF-PTC Therapeutics says total revenue for Q3 2016 was $23 mln” published on November 02, 2016, Marketwatch.com published: “PTC Therapeutics stock plummets 29% after FDA denies company’s DMD drug appeal” on October 17, 2016. More interesting news about PTC Therapeutics, Inc. (NASDAQ:PTCT) were released by: Prnewswire.com and their article: “PTC Therapeutics to Host Conference Call to Discuss Third Quarter Financial …” published on October 19, 2016 as well as Prnewswire.com‘s news article titled: “PTC Therapeutics Announces New Analyses that Support the Potential Benefit of …” with publication date: October 06, 2016.
PTCT Company Profile
PTC Therapeutics, Inc., incorporated on March 31, 1998, is a biopharmaceutical firm focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that focus on post-transcriptional control processes. The Company’s internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Company’s lead product, Translarna (ataluren), is used for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD) in ambulatory patients with age of over five years and older in over 30 member states of the European Economic Area (EEA). It holds commercialization rights to Translarna for all indications in all territories, across the world. Translarna is designated as an orphan medicinal product for the treatment of cystic fibrosis (CF), duchenne muscular dystrophy (DMD), Mucopolysaccharidosis type I (MPS I), and aniridia. The Company’s programs include Translarna for nmDMD, Translarna for nonsense mutation cystic fibrosis (nmCF), Translarna for mucopolysaccharidosis type I caused by nonsense mutation (nmMPS I), Translarna for nonsense mutation aniridia, Translarna for nonsense mutation Dravet syndrome/CDKL5, Spinal muscular atrophy (SMA) collaboration with Spinal Muscular Atrophy Foundation (SMA Foundation) and F. Hoffman-La Roche Ltd and Hoffman- La Roche Inc. (collectively Roche), and Cancer stem cell program (PTC596).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.